HK1078783A1 - Multistage formulation containing a biguanide and thiazolidindione derivatives - Google Patents
Multistage formulation containing a biguanide and thiazolidindione derivativesInfo
- Publication number
- HK1078783A1 HK1078783A1 HK05110822.8A HK05110822A HK1078783A1 HK 1078783 A1 HK1078783 A1 HK 1078783A1 HK 05110822 A HK05110822 A HK 05110822A HK 1078783 A1 HK1078783 A1 HK 1078783A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- biguanide
- multistage
- formulation containing
- thiazolidindione
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41218002P | 2002-09-20 | 2002-09-20 | |
US41218102P | 2002-09-20 | 2002-09-20 | |
PCT/US2003/029292 WO2004026241A2 (en) | 2002-09-20 | 2003-09-19 | Multistage formulation containing a biguanide and thiazolidindione derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1078783A1 true HK1078783A1 (en) | 2006-03-24 |
Family
ID=32033587
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05110822.8A HK1078783A1 (en) | 2002-09-20 | 2005-11-28 | Multistage formulation containing a biguanide and thiazolidindione derivatives |
HK10104549.6A HK1136780A1 (en) | 2002-09-20 | 2010-05-11 | Multistage formulation containing a biguanide and thiazolidindione derivatives |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10104549.6A HK1136780A1 (en) | 2002-09-20 | 2010-05-11 | Multistage formulation containing a biguanide and thiazolidindione derivatives |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP1539144B1 (sl) |
JP (1) | JP4694841B2 (sl) |
KR (4) | KR20120034211A (sl) |
CN (2) | CN101623274B (sl) |
AU (1) | AU2003272504A1 (sl) |
CA (1) | CA2499597C (sl) |
ES (1) | ES2529180T3 (sl) |
HK (2) | HK1078783A1 (sl) |
WO (1) | WO2004026241A2 (sl) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8323692B2 (en) * | 2002-02-21 | 2012-12-04 | Valeant International Bermuda | Controlled release dosage forms |
US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7785627B2 (en) * | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
NZ541749A (en) * | 2003-01-29 | 2009-06-26 | Takeda Pharmaceutical | Process for producing coated preparation comprising pioglitazone hydrochloride and a coating material |
UY29445A1 (es) * | 2005-03-30 | 2006-10-02 | Generex Pharm Inc | Composiciones para la transmisión transmucosa oral de la metformina |
US8414921B2 (en) * | 2005-12-16 | 2013-04-09 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
US8747897B2 (en) * | 2006-04-27 | 2014-06-10 | Supernus Pharmaceuticals, Inc. | Osmotic drug delivery system |
EP2019669B1 (en) * | 2006-05-23 | 2011-11-23 | Takeda Pharmaceutical Company Limited | Oral preparation comprising pioglitazone |
DE102008059206A1 (de) * | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
US9416098B2 (en) * | 2010-01-06 | 2016-08-16 | Immunomet Therapeutics Inc. | Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient |
JP2013533241A (ja) * | 2010-06-22 | 2013-08-22 | ティダブリューアイ・ファーマシューティカルズ・インコーポレイテッド | 食物効果が減少した制御放出組成物 |
EP2611434A1 (en) | 2010-09-01 | 2013-07-10 | Lupin Limited | Pharmaceutical composition comprising metformin and pioglitazone |
CN102008472B (zh) * | 2010-10-18 | 2012-08-22 | 中国科学院上海药物研究所 | 一种复方盐酸吡格列酮/盐酸二甲双胍双层渗透泵控释制剂及其制备方法 |
CN101984974B (zh) * | 2010-11-15 | 2013-04-17 | 山东新华制药股份有限公司 | 一种用于治疗2型糖尿病的药物组合物的制备方法 |
CN105663130B (zh) * | 2011-04-15 | 2019-08-09 | 江苏豪森药业集团有限公司 | 一种具有第一和第二活性药物的制剂 |
BR112014008744A2 (pt) | 2011-10-21 | 2017-04-18 | Takeda Pharmaceuticals Co | preparação de libertação prolongada, e, métodos para produzir uma preparação de liberação prolongada, e para prevenir e/ou retardar o início ou suprimir a progressão da doença de alzheimer |
UY35006A (es) * | 2012-09-06 | 2014-03-31 | Bayer Healthcare Llc | Composición farmacéutica recubierta que contiene regorafenib |
CN102920704A (zh) * | 2012-11-05 | 2013-02-13 | 上海现代药物制剂工程研究中心有限公司 | 含有双胍和噻唑烷二酮衍生物的药物制剂 |
WO2014184742A1 (en) | 2013-05-13 | 2014-11-20 | Ranbaxy Laboratories Limited | Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent |
JP6487031B2 (ja) | 2014-04-17 | 2019-03-20 | イミューノメット セラピューティクス インコーポレイテッド | グアニジン化合物、及びその用途 |
MA39929A (fr) * | 2014-11-27 | 2016-06-01 | Arven Ilac Sanayi Ve Ticaret As | Comprimé multicouche comprenant de la metformine et du pioglitazone |
CN104473894A (zh) * | 2014-12-18 | 2015-04-01 | 浙江华海药业股份有限公司 | 一种盐酸吡格列酮载药包衣制剂及其制备方法 |
CN106137999A (zh) * | 2015-03-31 | 2016-11-23 | 深圳翰宇药业股份有限公司 | 一种复方吡格列酮二甲双胍缓释片及其制备方法 |
KR101750690B1 (ko) * | 2015-10-28 | 2017-06-27 | 주식회사 종근당 | 메트포르민 및 로베글리타존을 포함하는 약제학적 조성물 |
CN108478537A (zh) * | 2018-05-03 | 2018-09-04 | 南京易亨制药有限公司 | 一种含普瑞巴林的单室渗透泵控释片剂 |
WO2021242040A1 (ko) * | 2020-05-29 | 2021-12-02 | 한국유나이티드제약 주식회사 | 삼투압에 의해 방출 조절되는 서방성 메트포르민 코팅 정제 및 이의 제조방법 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
FR2243684B1 (sl) | 1973-09-19 | 1977-01-28 | Semb | |
US4080472A (en) | 1974-03-22 | 1978-03-21 | Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. | Metformin 2-(p-chlorophenoxy)-2-methylpropionate |
US3952741A (en) | 1975-01-09 | 1976-04-27 | Bend Research Inc. | Controlled release delivery system by an osmotic bursting mechanism |
US4034758A (en) | 1975-09-08 | 1977-07-12 | Alza Corporation | Osmotic therapeutic system for administering medicament |
US4036228A (en) | 1975-09-11 | 1977-07-19 | Alza Corporation | Osmotic dispenser with gas generating means |
US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4522625A (en) | 1982-09-29 | 1985-06-11 | Alza Corporation | Drug dispenser comprising wall formed of semipermeable member and enteric member |
US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US4587117A (en) | 1983-06-06 | 1986-05-06 | Alza Corporation | Medical device for delivering drug to pH environments greater than 3.5 |
US4851229A (en) | 1983-12-01 | 1989-07-25 | Alza Corporation | Composition comprising a therapeutic agent and a modulating agent |
US4777049A (en) | 1983-12-01 | 1988-10-11 | Alza Corporation | Constant release system with pulsed release |
AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
US4892739A (en) | 1988-04-25 | 1990-01-09 | Ciba-Geigy Corporation | Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties |
US5071607A (en) | 1990-01-31 | 1991-12-10 | Alza Corporatino | Method and apparatus for forming a hole in a drug dispensing device |
US5178866A (en) | 1990-03-23 | 1993-01-12 | Alza Corporation | Dosage form for delivering drug to the intestine |
US5178867A (en) | 1991-08-19 | 1993-01-12 | Alza Corporation | Dosage form for delivering drug in short-time period |
DE4432757A1 (de) | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
US6011049A (en) | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
US5859037A (en) | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
US6153632A (en) | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
CZ298469B6 (cs) * | 1997-06-18 | 2007-10-10 | Smithkline Beecham Plc | Farmaceutický prostredek obsahující 5-[4-/2-(N-methyl-N-(2-pyridyl)amino)ethoxy/benzyl]thiazolidin-2,4-dion a metformin, a lécivo pro lécení diabetesmellitus |
FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
EA003101B1 (ru) | 1998-03-19 | 2002-12-26 | Бристол-Майерз Сквибб Компани | Двухфазная система доставки с регулируемым высвобождением для фармацевтических средств с высокой растворимостью и способ лечения диабета с помощью этой системы |
US6099859A (en) * | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
US6099862A (en) * | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6290699B1 (en) | 1999-07-07 | 2001-09-18 | Uab Research Foundation | Ablation tool for forming lesions in body tissue |
WO2001035940A2 (en) * | 1999-11-16 | 2001-05-25 | Smithkline Beecham P.L.C. | Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride |
MY125516A (en) * | 1999-11-16 | 2006-08-30 | Smithkline Beecham Plc | Novel composition based on thiazolidinedione and metformin and use |
JP2003518487A (ja) * | 1999-12-23 | 2003-06-10 | ファイザー・プロダクツ・インク | ヒドロゲル駆動型積層薬物製剤 |
SE0001151D0 (sv) * | 2000-03-31 | 2000-03-31 | Amarin Dev Ab | Method for producing a controlled-release composition |
US6524621B2 (en) | 2000-05-01 | 2003-02-25 | Aeropharm Technology Inc. | Core formulation |
US6451342B2 (en) | 2000-05-01 | 2002-09-17 | Aeropharm Technology Incorporated | Core formulation comprised of troglitazone and a biguanide |
US6780432B1 (en) * | 2000-05-01 | 2004-08-24 | Aeropharm Technology, Inc. | Core formulation |
DE10025946A1 (de) * | 2000-05-26 | 2001-11-29 | Gruenenthal Gmbh | Wirkstoffkombination |
US20030086972A1 (en) * | 2000-08-09 | 2003-05-08 | Appel Leah E. | Hydrogel-driven drug dosage form |
US20030224046A1 (en) * | 2002-06-03 | 2003-12-04 | Vinay Rao | Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent |
-
2003
- 2003-09-19 KR KR1020127002220A patent/KR20120034211A/ko active Application Filing
- 2003-09-19 KR KR1020137005362A patent/KR101363679B1/ko not_active IP Right Cessation
- 2003-09-19 KR KR1020107027556A patent/KR20100137023A/ko active Application Filing
- 2003-09-19 KR KR1020057004787A patent/KR20050053677A/ko active Search and Examination
- 2003-09-19 ES ES03754689.2T patent/ES2529180T3/es not_active Expired - Lifetime
- 2003-09-19 CN CN2009101611482A patent/CN101623274B/zh not_active Expired - Fee Related
- 2003-09-19 EP EP03754689.2A patent/EP1539144B1/en not_active Expired - Lifetime
- 2003-09-19 AU AU2003272504A patent/AU2003272504A1/en not_active Abandoned
- 2003-09-19 CN CNB038223627A patent/CN100544717C/zh not_active Expired - Fee Related
- 2003-09-19 WO PCT/US2003/029292 patent/WO2004026241A2/en active Application Filing
- 2003-09-19 CA CA2499597A patent/CA2499597C/en not_active Expired - Fee Related
- 2003-09-19 JP JP2004537943A patent/JP4694841B2/ja not_active Expired - Fee Related
- 2003-09-19 EP EP13001210.7A patent/EP2604266A1/en not_active Withdrawn
-
2005
- 2005-11-28 HK HK05110822.8A patent/HK1078783A1/xx not_active IP Right Cessation
-
2010
- 2010-05-11 HK HK10104549.6A patent/HK1136780A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN100544717C (zh) | 2009-09-30 |
KR20130039344A (ko) | 2013-04-19 |
KR20100137023A (ko) | 2010-12-29 |
CN101623274A (zh) | 2010-01-13 |
KR101363679B1 (ko) | 2014-02-14 |
HK1136780A1 (en) | 2010-07-09 |
CN1681496A (zh) | 2005-10-12 |
CN101623274B (zh) | 2012-06-27 |
AU2003272504A8 (en) | 2004-04-08 |
EP1539144A2 (en) | 2005-06-15 |
WO2004026241A3 (en) | 2004-06-10 |
EP2604266A1 (en) | 2013-06-19 |
JP4694841B2 (ja) | 2011-06-08 |
CA2499597C (en) | 2012-01-17 |
ES2529180T3 (es) | 2015-02-17 |
AU2003272504A1 (en) | 2004-04-08 |
KR20050053677A (ko) | 2005-06-08 |
CA2499597A1 (en) | 2004-04-01 |
EP1539144B1 (en) | 2014-12-24 |
JP2006502187A (ja) | 2006-01-19 |
KR20120034211A (ko) | 2012-04-10 |
EP1539144A4 (en) | 2010-06-09 |
WO2004026241A2 (en) | 2004-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1136780A1 (en) | Multistage formulation containing a biguanide and thiazolidindione derivatives | |
IL221199A (en) | A fragrance-containing drug | |
IL162548A0 (en) | 4-Oxoquinoline derivatives and pharmaceutical compositions containing the same | |
IL166482A0 (en) | Dihydropyrazolopyridine derivatives and pharmaceutical compositions containing the same | |
IL164890A0 (en) | Thiophene amidine derivatives and pharmaceutical compositions containing the same | |
IL166129A0 (en) | Pyrrolotriazine derivatives and pharmaceutical compositions containing the same | |
AU2003297382A1 (en) | Absorbent article having a color-pigmented and printed backsheet | |
AU2003276549A8 (en) | Pharmaceutical compositions containing a biguanide-glitazone combination | |
EP1663170A4 (en) | NEW PHARMACEUTICAL FORMULATION WITH A BIGUANIDE AND A THIAZOLIDE INDION DERIVATIVE | |
AU2002257562A1 (en) | Deuterated 3-Piperidinopropiophenone and medicaments containing said compounds | |
IL163868A0 (en) | Hermiasterlin derivatives and uses thereof | |
GB0207438D0 (en) | Formulation | |
AU2003216221A1 (en) | Attachment and articles using same | |
GB0205504D0 (en) | Formulation | |
EP1539239A4 (en) | NEW STABLE FORMULATION | |
HUP0303593A3 (en) | Biguanide derivatives, pharmaceutical compositions containing them and their use | |
AU2003241537A8 (en) | Biguanide formulations | |
AU2003221179A1 (en) | Modular electronic device | |
AU2003241920A1 (en) | Antimicrobial envelopes | |
IL161496A0 (en) | A combination product comprising melagatran and dexamethasone | |
EP1499338A4 (en) | 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSENES-17-ONE AND 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSTAN-17-ONE AND THEIR DERIVATIVES | |
GB0212985D0 (en) | Article handling | |
EP1486483A4 (en) | N-BIPHENYLAMIDES AND FUNGICIDES CONTAINING THEREOF | |
IL163627A0 (en) | Aminoalcohol derivatives and pharmaceutical compositions containing the same | |
AU2002100309A4 (en) | Laddaloc (a colapsable and lockable ladder) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20170919 |